Here are four things to know:
1. EndoBarrier Therapy is an endoscopically-delivered device therapy for those suffering from uncontrolled type-2 diabetes and obesity.
2. The decision to hold further enrollment is due to the fact that there have been four cases of hepatic abscess among the 325 subjects currently enrolled in the ENDO Trial.
3. The FDA is thus requesting additional information to further assess the risk/benefit profile of the EndoBarrier Therapy.
4. According to a press release, GI Dynamics has already implemented several risk mitigation strategies in the ENDO Trial and is working to submit the requested information to the FDA.
More articles on GI/endoscopy:
UMass Memorial Medical Group adds Dr. Kerri Gosselin — 3 quick facts
Tissue-engineered small intestine successful — Is a new short bowel syndrome treatment next? 3 things to know
Cahaba GBA to cover EndoGastric Solutions’ TIF procedure: 4 important takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.